Skip to content

Search

COVID-19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non-malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement

The Australian Technical Advisory Group on Immunisation and New Zealand Ministry of Health recommend all children aged ≥ 5 years receive either of the two mRNA COVID-19 vaccines: Comirnaty (Pfizer), available in both Australia and New Zealand, or Spikevax (Moderna), available in Australia only. Both vaccines are efficacious and safe in the general population, including children. Children and adolescents undergoing treatment for cancer and immunosuppressive therapy for non-malignant haematological conditions are particularly vulnerable, with an increased risk of severe or fatal COVID-19.

COVID-19 Vaccine Mandates: Attitudes and Effects on Holdouts in a Large Australian University Population

Many governments and institutions mandated COVID-19 vaccines. In late 2021, we sought to ascertain the perspectives of staff and students from The University of Western Australia about the State or the University mandating COVID-19 vaccines.

Flexible societies excelled in saving lives in the first phase of the COVID-19 pandemic

Previous studies have shown that national cultural traits, such as collectivism–individualism and tightness–looseness, are associated with COVID-19 infection and mortality rates.

Parents' Experiences of Childhood Cancer During the COVID-19 Pandemic: An Australian Perspective

COVID-19 has had far-reaching impacts including changes in work, travel, social structures, education, and healthcare. This study aimed to explore the experiences of parents of children receiving treatment for cancer during the COVID-19 pandemic.

Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021

Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or breakthrough infection, which can become refractory to antifungal treatment and has a high associated mortality. Other emerging patient risk groups include patients in the intensive care setting with severe respiratory viral infections, including COVID-19.

Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents

Christopher Blyth MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Evaluation of protocol amendments to the Environmental Determinants of Islet Autoimmunity (ENDIA) study during the COVID-19 pandemic

Liz Davis MBBS FRACP PhD Co-director of Children’s Diabetes Centre Co-director of Children’s Diabetes Centre Professor Davis is a paediatric

COVID-19

Here’s what we know so far about the impact of COVID-19 on children.

COVID-19 Research

Thanks to 30 years of support from the WA community, The Kids Research Institute Australia is home to some of the world’s best researchers.

Questions about COVID-19 and kids

With the number of COVID-19 infections in Western Australia continuing to grow – including confirmed cases in children – The Kids Research Institute Australia understands that our community is growing increasingly worried.